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Background: BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been
implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate
increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen
for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP
inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. Exploiting the
genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA
mutated cancers.
Methods: This multi-centre phase II single arm trial was designed to investigate the activity and safety of
6-mercaptopurine (6MP) 55 mg/m2 per day, and methotrexate 15 mg/m2 per week in patients with advanced
breast or ovarian cancer, ECOG PS 0–2, progressing after ≥ one prior regimen and known to bear a BRCA1/2 germ
line mutation. Accrual was planned in two stages, with treatment continuing until progression or unacceptable
toxicity; in the first, if less than 3/30 evaluable patients respond at 8 weeks after commencing treatment, the trial
will be stopped for futility; if not, then accrual would proceed to a second stage, in which if more than 9/65
evaluable patients are found to respond at 8 weeks, the treatment will be regarded as potentially effective and a
phase III trial considered subject to satisfactory safety and tolerability. The primary outcome is objective response at
8 weeks, defined by RECISTS v1.1 as complete response, partial response or stable disease. Secondary outcomes
include safety, progression- free and overall survival, and quality of life.
Discussion: This study aims to investigate whether 6MP might be an effective treatment for BRCA deficient
tumours even after the development of resistance to PARP inhibitors or platinum drugs. The study has surpassed
the first stage analysis criteria of more than 3 out of 30 evaluable patients responding at 8 weeks, and is currently
in the second stage of recruitment.
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Ovarian cancer is the fourth most common cause of
cancer mortality in women; the majority (75%) of ovar-
ian cancer patients will present with late stage disease
(International Federation of Gynaecology and Obstetrics
(FIGO) stage III/IV), and the overall prognosis remains
poor with five year survival rates of 30- 40%. Current
first line chemotherapy for ovarian cancer usually com-
prises of a combination of carboplatin and paclitaxel.
Despite complete remissions in approximately 75% of
patients, responses are generally short lived, with
median progression-free survival (PFS) ranging from
16–21 months [1]. Despite initial response rates of 65-
80% to first line chemotherapy, the majority of patients
will relapse and ultimately develop resistance to further
chemotherapy.
Breast cancer is the most common cancer in the UK;
around 55,000 people are diagnosed each year. There are
currently multiple options for the treatment of patients
with advanced breast cancer, including hormone therapy,
chemotherapy and Her-2-directed therapy, as well as
possible radiotherapy and/or surgery for patients with
symptomatic oligo-metastatic disease, thus most breast
cancer patients with advanced stage disease will receive
multiple lines of therapy.
BRCA1 and BRCA2 genes play an important role in
homologous recombination DNA repair and have been im-
plicated in familial breast and ovarian cancer syndromes.
In addition to germline BRCA1/2 mutations, silencing of
BRCA1/2 expression can also occur via epigenetic pro-
cesses such as promoter hyper- methylation and this has
been documented in 11-14% of breast cancers [2] and
11-35% of ovarian cancer patients [3].
For patients with metastatic cancer, the challenge is to
develop better treatment strategies to maximise tumour
cell kill and minimise toxicity. In patients with BRCA1/
2 deficient cancers, one such approach has been to
develop molecular targeted therapy using PARP inhibi-
tors that selectively exploit biological pathways within
tumour cells, which differ from those in normal cells
and wider concepts of genetic synthetic lethality [4-6].
PARP is a nuclear enzyme activated in response to DNA
single strand breaks and is involved in repair of these
lesions via the base excision pathway (BER). The main
lesions formed by cisplatin are intra-strand crosslinks
between closely adjacent purine bases [7]. Efficient BER
is also required for repair of these lesions. An inability
to couple DNA damage to an apoptotic signal path-
way may lead to the development of resistance to
platinum and PARP inhibitors. Tumours may also ac-
quire resistance by additional mutations in the BRCA1 &
BRCA2 gene [8-10] and so there is a place for further
investigation of DNA repair inhibition in HR defective
tumours.Carriers of BRCA mutations have an increased lifetime
risk of developing breast or ovarian cancer and in these
families the focus has been on prevention (screening for
early detection or prophylactic surgery). Hitherto, once
cancers have developed in these patients they have gen-
erally received standard therapy for that tumour type.
However patients with a BRCA1/2 mutation have an
increased sensitivity to agents that cause DNA damage
through double stranded breaks or DNA cross-links,
such as platinum agents due to the genetic basis of their
tumours. Recent clinical studies with cisplatin based
chemotherapy and PARP inhibitors have sought to exploit
the genetic basis of these tumours in order to develop a
more tailored approach to therapy for patients with breast
and ovarian cancer and known BRCA mutations and/or
suspected defects in homologous recombination (defined
as patients with triple receptor negative (oestrogen, pro-
gesterone and HER2 receptor-negative) breast cancer, or
advanced high grade serous ovarian cancer with a history
of repeated platinum sensitivity).
The thiopurines 6-mercaptopurine (6MP) and 6-
thioguanine (6TG) are growth inhibitory antimetabolites
licensed for the treatment of acute leukaemias and also
chronic granulocytic leukaemia. Structurally, these agents
are purine analogues that interfere with nucleic acid
biosynthesis. Methotrexate is also an antimetabolite and
inhibits tetrahydrofolate dehydrogenase and prevents
formation of tetrahydrofolate, which is required for syn-
thesis of thymidylate, an essential component of DNA. It
is routinely used in combination with 6MP in patients
with ALL as it has been shown to reduce de novo purine
synthesis and thus enhance the cytotoxicity of 6MP by
promoting its conversion to 6TGNs [11,12]. Methotrexate
has also been widely used in the treatment of a number of
solid tumours such as breast, ovarian, lung and cervical
cancers. Furthermore a recent synthetic lethality screen
has identified methotrexate as an agent that has activity in
DNA mismatch repair (MMR) defective cancers, as evi-
denced by its selective toxicity in cells lacking functional
mutS homolog 2 (MSH2) gene mutations [13].
The rationale for our study is based on in-vitro work
by Issaeva et al. [14] who have shown that 6- thiogua-
nine (6TG) selectively kills BRCA2-defective cells as
effectively as the PARP inhibitor, AGO14699. Even after
cells have acquired resistance to a PARP inhibitor or
cisplatin, they retain sensitivity to 6TG. However as long
term administration of 6TG is problematic due to dose
related toxicities, such as veno- occlusive disease, this study
will assess the activity of 6-mercaptopurine (6MP), which
is converted to the same active moiety, 6-thioguanine
nucleotide, prior to incorporation into DNA. Low dose
methotrexate will be used in combination with 6MP in
this study as it promotes the formation of thioguanine
nucleotides.
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The primary objective of the 6MP study is to determine
the objective tumour response rate to 6-mercaptopurine
(6MP) and low-dose methotrexate in patients with previ-
ously treated breast, ovarian, fallopian tube or primary
serous peritoneal cancer who are known to have a BRCA
mutation, 8 weeks after starting treatment. Secondary
objectives include progression-free survival (PFS), overall
survival (OS), safety, toxicity, pharmacokinetics; and quality
of life. Exploratory objectives include evaluation of patients’
Mismatch Repair (MMR) status at initial diagnosis, prior
to starting the study, and after 7 weeks of treatment. An
assessment of the feasibility of this trial in a multi-centre




The 6MP study is a single arm, non-randomised, two-
stage, multi-centre Phase II trial. The trial opened in June
2011 and recruits from 14 centres across the UK. Follow-
ing written informed consent and screening tests, eligible
patients will commence treatment, taking 6MP once daily
and methotrexate once weekly. Treatment will continue
until disease progression or unacceptable toxicity. Conduct
of the 6MP trial complies with the ethical principles of the
Declaration of Helsinki (1996) and the regulatory require-
ments for clinical trials of an investigational medicinal
product under the European Union Clinical Trials Direct-
ive. The study has been approved by the National Research
Ethics Service (NRES) Committee South Central – Oxford
B (REC reference 10/H0605/79).
The trial is sponsored by the University of Oxford, with
funding from Cancer Research UK’s Clinical Trials Award
and Advisory Committee (CTAAC) who approved a full
funding application on 26th October 2010, and this work
was supported by the Oxford Partnership Comprehensive
Biomedical Research Centre with funding from the De-
partment of Health’s National Institute of Health Research
(NIHR) Biomedical Research Centre funding scheme.
Data submission for the 6MP trial is via electronic
submission into the online database system OpenClinica
by site staff, and this is closely monitored. The Oncology
Clinical Trial Office (OCTO) coordinates the trial, and
OCTO staff are in charge of the day-to-day running of the
trial, as well as managing the trial as a whole; organising
trial meetings, completing trial documentation, site moni-
toring, and database management. All statistical analysis
will be undertaken by statisticians at the Centre for Statis-
tics in Medicine (CSM) at the University of Oxford.
Participants
To be eligible for inclusion in the 6MP study, patients
must be aged 18 or older, have proven BRCA1 or BRCA2mutations, and have measurable disease as defined by
RECIST v1.1 criteria. For breast cancer patients, patients
must have locally advanced or metastatic breast cancer,
and may have received up to 3 previous lines of chemo-
therapy in the locally advanced or metastatic setting.
Ovarian, fallopian tube or primary serous peritoneal
cancer patients must have disease that is either platinum
resistant or in whom further platinum based therapy is
inappropriate. All patients must have an Eastern Coopera-
tive Oncology Group (ECOG) performance score between
0 and 2, a life expectancy of greater than 12 weeks, and
adequate haematological and biochemical function. Pa-
tients are excluded from participating in the study if they
have a Low/Low genotype on Thiopurine methyltransfer-
ase (TPMT) testing. Patients with low activity (10% preva-
lence) or especially absent activity (prevalence 0.3%) are at
a heightened risk of drug-induced bone marrow toxicity
due to accumulation of the unmetabolised 6MP. At the
start of the trial, patients were excluded from participation
if they had low TPMT activity (<68 U/ml), but a decision
was made by the 6MP TMG in October 2013 to remove
this exclusion as a substantial amendment to the protocol,
as evidence suggested that moderate TPMT activity levels
did not affect dose intensity or levels of myelosuppression
seen. Patients were already being closely monitored in the
first cycle therefore no additional monitoring was imple-
mented for this patient group. A total of 14 sites across
the UK are actively recruiting for this trial; Royal United
Hospital, Bath; Belfast City Hospital, Belfast; Velindre
Hospital, Cardiff; University Hospital, Coventry and
Warwickshire; Western General Hospital, Edinburgh;
Guy’s Hospital, London; Royal Marsden Hospital, London;
University College London Hospital, London; Christie
Hospital, Manchester; Freeman Hospital, Newcastle;
Mount Vernon Hospital, Middlesex; Churchill Hospital,
Oxford; Royal Marsden Hospital, Sutton; Clatterbridge,
Wirral.
Interventions
Patients in the trial are treated with 6-mercaptopurine
(6MP) and methotrexate continuously in 28 day cycles
until disease progression or unacceptable toxicity. The
dose of 6MP given is 55 mg/m2 body surface area, admin-
istered orally once a day at least one hour after eating;
tablets should be taken at roughly the same time each day.
A 15 mg/m2 dose of methotrexate should be taken orally
once a week in the morning. It should be noted that these
starting doses are not those originally set at the beginning
of the trial. Doses were originally 75 mg/m2 of 6MP daily,
and 20 mg/m2 of methotrexate weekly, but these were
reduced following an Urgent Safety Measure in August
2012 due to a large proportion of patients requiring a dose
reduction or treatment delay due to incidences of myelo-
suppression. Although myelosuppression is an expected
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did not have serious safety concerns, the Trial Manage-
ment Group concurred that a dose reduction was indicated
to ensure dose intensity could be maintained without
compromising patient safety.
Outcomes and assessments
The primary outcome of the 6MP study is objective
response, defined as complete response (CR), partial
response (PR), or stable disease (SD), as measured by
radiological disease response using RECIST criteria
version 1.1. Patients who yield progressive disease (PD)
are classed as non-responders. Tumour size is measured
radiologically with computerised tomography (CT) and/or
magnetic resonance imaging (MRI); the same method
is used at baseline and at follow-up. The first time
point for this primary analysis is 8 weeks after first
treatment.
Secondary outcome measures include safety, overall
survival (OS) and progression-free survival (PFS). Length
of overall survival is defined in whole days as the time
from entry into the study until death from any cause,
and those patients who are not observed to die during
the course of the trial will be censored at their last
known follow-up date. Length of progression-free survival
is defined in whole days as the time from entry into the
study until progression or death from any cause, and those
patients who are not observed to progress or die during
the course of the trial will be censored at their last known
progression- free follow-up date. Grade 3 or 4 Adverse
Events (AEs), as defined by the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0, and abnormal clinical and labora-
tory findings will be collected at regular follow-up visits
throughout the trial in order to evaluate safety. Pharmaco-
kinetics are measured by the assessment of red blood cell
6-thioguanine nucleotide (6TGN) levels using a validated
high-performance liquid chromatography (HPLC) assay,
and the effect of pharmacogenomics on thiopurine metab-
olism is measured by assessing the TPMT genotype using
a validated assay. Another secondary outcome is quality of
life, which is evaluated using the EQ-5D questionnaire at
baseline, 3 and 6 months, and at the end of treatment or
12 months, as well as using the ECOG performance status
measure after each cycle.
Recruitment is monitored throughout the trial, in
order to assess the feasibility of the 6MP study as a
multi- centre study. If each site recruits 3–4 patients per
year, this indicates that a large randomised phase III
study would be feasible. The exploratory outcome meas-
ure of the 6MP trial is the Mismatch Repair (MMR) sta-
tus of each patient; this will be assessed using validated
immunohistochemical/MSI assays using tissue from ini-
tial diagnosis, just prior to starting the study, and after7 weeks of treatment, as well as from optional extra
biopsies.
Sample size determination and power
The 6MP study aims to recruit 30 evaluable patients in
the first stage, and 65 patients in total. The Simon com-
promise/admissible two-stage design [15,16] was imple-
mented to calculate this required sample size to detect an
increase in response rate from 10% to 20%, with a power
of 90% and a significance level of
20%. In the first stage of the study, if fewer than 3 out
of 30 evaluable patients respond at 8 weeks after first
treatment, then the trial will be stopped for futility; if 3
or more respond then a further 35 patients will be recrui-
ted in the second stage. If nine or more of the total 65
patients respond at 8 weeks then the treatment will be
regarded as potentially effective and a phase III rando-
mised trial will then be considered, if, in addition, the
treatment appears to be safe and well tolerated, and the
trial roll-out over multiple centres proves feasible.
Statistical analysis
In the 6MP trial, fully evaluable patients (the per proto-
col population) are those patients who complete at least
4 out of 8 weeks of trial medication and are assessed for
response as per RECIST v1.1 at 8 weeks. Patients who
stop trial medication early due to disease progression
(assessed by RECIST v1.1) are also fully evaluable because
they have reached an end point. Partially evaluable pa-
tients (the intention to treat population) are those patients
who have received at least one dose of treatment and who
have a response assessment. Additional patients may be
recruited at the discretion of the Chief Investigator to
replace any that are not evaluable.
The proportion of patients responding to treatment
will be presented, together with 95% confidence intervals,
for Stage 1 (30 evaluable patients) and overall (65 evalu-
able patients). The number and proportion of patients
who achieve CR, PR, SD and PD will also be reported,
overall and separately for those patients who had received
prior treatment with PARP inhibitors.
Overall survival and progression-free survival will both
be presented overall and separately for patients previously
treated with PARP inhibitors using Kaplan Meier graphs,
and summarised as 1 and 2 year survival, together with
their two-sided 95% confidence intervals. Median and
quartile OS and PFS will also be presented. If the assump-
tion of proportional hazards is met, the univariate hazard
ratio (HR) from the Cox proportional hazards regression
model will be given. In the case where the assumption of
proportional hazards is inappropriate, parametric hazard
functions will be considered.
Quality of life data will be presented descriptively
overall and separately for patients previously treated
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using the NCI CTCAE version 4.0. Adverse Events (AEs)
and Serious Adverse Events (SAEs) will be summarised by
incidence rates and classified by the worst severity grade
observed.
Interim analysis
A safety interim analysis was undertaken 3 months after
the first 12 patients were recruited into the trial and had
received at least one dose of the trial drugs. No issues
with safety were found in this review, and any observed
side effects were found to be as expected for this patient
group. Another interim analysis was carried out 8 weeks
after the first 30 patients were recruited (at the end of
stage one), and again no safety concerns were raised and
the events reported were found to be as expected. Also
at this interim analysis stage, the first milestone was
reached and passed, and a further 35 patients are now
currently being recruited.
Monitoring committees
The Independent Early Phase Trials Oversight Committee
(IEPTOC) are responsible for providing overall supervi-
sion of the trial; in particular trial progress, adherence to
protocol, patient safety and consideration of new informa-
tion. An Internal Safety Monitoring Committee is also in
place for 6MP, consisting of the chief investigator, trial
statistician, a member of the 6MP trial office, and an inde-
pendent oncologist. This committee evaluate the ongoing
safety of the trial participants, and also reviewed all safety
interim analyses.
Ethical approval
Obtained from the National Research Ethics Service
(NRES) Committee South Central – Oxford B. Rec refer-
ence number 10/H0605/79.
Discussion
The in vitro and in vivo findings of Issaeva and colleagues
[14] suggest that 6TG might be an effective treatment in
BRCA deficient tumours as a first line treatment or after
developing resistance to PARP inhibitors or platinum
drugs. 6TG is not recommended for continuous therapy
due to its hepatotoxicity, but the antimetabolite 6MP,
which is structurally similar to 6TG, has been shown to
have comparable efficacy in patients with acute lympho-
blastic leukaemia. To our knowledge, there have been no
other studies comparing the efficacy of 6TG and 6MP in
patients with solid malignancies. The aim of the 6MP trial
is to evaluate the efficacy and safety of 6MP in combin-
ation with low dose methotrexate in patients with breast
or ovarian cancer who are known to have a BRCA muta-
tion, who have progressed after at least one previous line
of chemotherapy. Exploiting the genetic basis of thesetumours enables us to develop a more tailored approach
to therapy for patients in this cohort.Confidentiality, dissemination of results and
publication policy
Information collected during the trial is considered
strictly confidential and will be securely stored with re-
stricted access in accordance with the Data Protection
Act. To protect the participant's identity, only initials
and date of birth along with an assigned trial number
will be used as patient identifiers. It is clearly stated in
lay terms in the Patient Information Sheet and as a separ-
ate point within the Consent Form that authorised staff
from the local Trust R&D office, the research team based
at each study site, OCTO personnel during on site moni-
toring visits, and auditors from regulatory bodies may
have access to their patient records.
The Sponsor recognises that participating Investigators
have a responsibility under the Research Governance
Framework for Health and Social Care to ensure that
results of scientific interest arising from the Study are
appropriately published and disseminated. The Chief
Investigator will ensure public disclosure of the clinical
trial research results in the form of a peer reviewed
scientific journal publication and for other academic
research purposes as appropriate. Participating site inves-
tigators will be provided with the full summary of results
and encouraged to share the summary of results with
study participants, as appropriate.Trial status
The trial is open for recruitment at the time of manu-
script submission.
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